Frova(R) Meets Primary Endpoint In Second Phase III Study For Prevention Of Menstrual Migraine

Wed, 10 May 2006 11:00 AM EST

... Vernalis plc (LSE: VER, Nasdaq: VNLS) and Endo Pharmaceuticals HoldingsInc. (Nasdaq: ENDP) today announced top-line data from the second Phase IIIefficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for theshort-term (six-days per month) prevention of menstrual migraine (MM). Thedata from this study corroborate the positive findings in a prior efficacystudy published in Neurology in July 2004 (ref: 2004, 63: 261-269)... click link for more info. ...